Stockscreener 앱 받기
458.05
1.43%
6.46
시간 외 거래:
458.00
-0.05
-0.01%
전일 마감가:
$451.59
열려 있는:
$454.5
하루 거래량:
1.30M
Relative Volume:
0.89
시가총액:
$116.36B
수익:
$12.07B
순이익/손실:
$3.95B
주가수익비율:
29.87
EPS:
15.3349
순현금흐름:
$3.19B
1주 성능:
-4.20%
1개월 성능:
-2.39%
6개월 성능:
+19.56%
1년 성능:
-10.63%
1일 변동 폭
$449.75
$459.45
1주일 범위
$449.75
$486.66
52주 변동 폭
$362.50
$515.67
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 업그레이드 | Maxim Group | Hold → Buy |
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-03-10 | 재확인 | Oppenheimer | Outperform |
| 2026-02-13 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2026-01-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2026-01-06 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 개시 | Raymond James | Mkt Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
Best Growth Stock to Buy Right Now: Eli Lilly vs. Vertex Pharmaceuticals - The Motley Fool
RBC Capital reiterates Vertex stock rating on competitive concerns - Investing.com
Swiss Life Asset Management Ltd Buys 6,045 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Wells Fargo Adjusts PT on Vertex Pharmaceuticals to $550 From $515, Maintains Overweight Rating - marketscreener.com
Argus Adjusts PT on Vertex Pharmaceuticals to $520 From $475, Maintains Buy Rating - marketscreener.com
Mirabella Financial Services LLP Raises Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
VRTX SEC FilingsVertex Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Groupama Asset Managment Sells 17,916 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Stock In Shambles: Down 9.5% With 6-Day Losing Streak - Trefis
Danske Bank A S Makes New $64.42 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by AIA Group Ltd - MarketBeat
Vertex Pharmaceuticals (VRTX) Upgraded to Buy by Maxim Group | V - GuruFocus
Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Vertex Pharmaceuticals (VRTX) Gains Amid Optimistic Outlook and Upgrade - GuruFocus
Q4 Earnings Outperformers: Vertex Pharmaceuticals (NASDAQ:VRTX) And The Rest Of The Therapeutics Stocks - Yahoo Finance
Vertex Pharmaceuticals Stock Slides 7.3% With A 5-Day Losing Spree - Trefis
Vertex Pharmaceuticals Stock Plummets -7.3% With 5-Day Losing Streak - Trefis
Vertex Pharmaceuticals Incorporated $VRTX is Provident Investment Management Inc.'s 4th Largest Position - MarketBeat
Physician Views Preview: How clinically meaningful are Vertex's Phase III data for povetacicept? - FirstWord Pharma
Insider Sell: Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex Pharmaceuticals (NASDAQ:VRTX) CMO Carmen Bozic Sells 2,329 Shares - MarketBeat
Vertex Pharmaceuticals EVP and CMO Carmen Bozic Sells Shares - TradingView
Vertex (VRTX) EVP and CMO Carmen Bozic sells 2,329 shares in pre-set 10b5-1 trade - Stock Titan
Top Biotech Stocks To Follow TodayMarch 17th - MarketBeat
Mirabella Financial Services LLP Has $2.10 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Focus Partners Wealth Trims Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bamco Inc. NY Trims Stake in Vertex Pharmaceuticals - National Today
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Bamco Inc. NY - MarketBeat
Bank of Nova Scotia Buys 36,643 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by California Public Employees Retirement System - MarketBeat
Aquatic Capital Management Boosts Vertex Pharmaceuticals Stake - National Today
Aquatic Capital Management LLC Acquires Shares of 29,596 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Layoff Tracker: Inovio Slims Down as Lead Asset Nears Market - BioSpace
S&P 500 Dips 0.21% as Vertex Pharmaceuticals Soars 8.31% Amid Market Struggles - Markets Mojo
Is Vertex Pharmaceuticals Heading to $600? - The Motley Fool
The week in pharma: action, reaction and insight – week to March 13, 2026 - The Pharma Letter
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Chevy Chase Trust Holdings LLC - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Boosts Vertex Pharmaceuticals Stake - National Today
Banco Bilbao Vizcaya Argentaria S.A. Buys 4,464 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Ameriprise Financial Inc. - MarketBeat
Aristotle Atlantic Partners LLC Decreases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Alliancebernstein L.P. Acquires 144,266 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Wellington Management Group LLP - MarketBeat
Prosight Management LP Boosts Vertex Pharmaceuticals Stake - National Today
Prosight Management LP Takes $8.03 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Insider Sell: Duncan Mckechnie Sells Shares of Vertex Pharmaceuticals Inc (VRTX) - GuruFocus
Vertex (VRTX) EVP McKechnie sells 2,633 shares at $498.42 - Stock Titan
What Vertex Pharmaceuticals (VRTX)'s IgA Nephropathy Win Means For Its Next Major Franchise Potential - simplywall.st
Carmen Bozic proposes sale of VRTX common stock (NASDAQ: VRTX) - Stock Titan
Landscape Capital Management L.L.C. Buys 7,405 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.90%
0.15%
자본화:
|
볼륨(24시간):